Abivax S.A.
NASDAQ:ABVXBiotechnology
-$0.62 today
- Market cap
- $7.34B
- Beta
- -0.20
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$4.83
Volume 1.19M
Average 1.59M
ABVX Interest Income
Income earned on cash, deposits, and investments held by the company.
Abivax S.A.NASDAQ: ABVX
Interest Income · Q2 FY2026 · quarter ended Jun 2026
Interest income grows 300.9% year over year
Q2 FY2026 interest income of €1.28M rose 300.9% year over year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
EUR · from the income statement
- Latest · FY2025
- 5.75M EUR
- Year-over-year change
- -35.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.75M | -35.8% |
| FY2024 | 2024-12-31 | 8.96M | +223.0% |
| FY2023 | 2023-12-31 | 2.77M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Interest Income vs competitors
How ABVX compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -35.8% is the 9th highest of 11, against a peer median of -7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $58M USD | +23.4% | +36.8% | 49.6% | |
| LTM Sep 2026 | $34.81M USD | +48.0% | +209.8% | 38.5% | |
| LTM Mar 2026 | $24.38M USD | -6.3% | +57.0% | 11.2% | |
| LTM Aug 2026 | $18.56M USD | -20.1% | +84.3% | 2.6% | |
| LTM Mar 2026 | $11.74M USD | -40.2% | +21.4% | 5.1% | |
| LTM Mar 2026 | $6.99M USD | -14.1% | — | 83.5% | |
| FY2025 | €5.75M EUR | -35.8% | — | — | |
| LTM Mar 2026 | $4.01M USD | -8.1% | — | 6803.4% | |
| FY2025 | €2.83M EUR | +147.5% | +93.6% | 63.1% | |
| LTM Mar 2026 | $1.12M USD | +24.8% | — | — | |
| LTM Mar 2026 | -$1.14M USD | -107.3% | +38.6% | — | |
| Peer median (excluding ABVX) | — | -7.2% | +57.0% | 44.0% | |
Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 45.52M | 50.76M | 0 | 0 | 0 |
| Gross Profit | (45.52M) | (50.76M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.78M | 48.3M | 103.18M | 146.53M | 177.76M |
| Selling, General & Admin | 5.58M | 7.49M | 28.82M | 38.9M | 72.87M |
| Operating Expenses | (4.12M) | 14.07M | 127.38M | 172.98M | 246.06M |
| Depreciation & Amortization | 302K | 485K | 707K | 1.1M | 1.07M |
| EBITDA | (38.59M) | (53.32M) | (133.21M) | (162.71M) | (300.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (41.4M) | (64.84M) | (127.38M) | (172.98M) | (246.06M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 2.77M | 8.96M | 5.75M |
| Interest Expense | 3.56M | 6.94M | 13.83M | 12.43M | 28.48M |
| Other Income / Expenses | (1.05M) | 4.1M | (20.36M) | (3.26M) | (84.2M) |
| Income Before Tax | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (330.25M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 5.85M |
| Net Income | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (336.1M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.75) | (3.18) | (3.43) | (2.80) | (4.65) |
| EPS (Diluted) | (2.75) | (3.18) | (3.43) | (2.80) | (4.65) |
| Weighted Avg Shares | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
| Weighted Avg Shares (Diluted) | 15.46M | 19.09M | 43.07M | 63.05M | 69.53M |
Abivax S.A.
NASDAQ:ABVX
Intrinsic Alpha fair value
Locked
Current Price
$83.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.